Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women

Journal of Bone and Mineral Metabolism

Volumn 25, Issue 2, 2007, Pages 105-113

  Pasion, Ellewellyn G ^a   Sivananthan, Shanmugam K ^b   Kung, Annie Wai Chee ^c   Chen, Sung Hsiung ^d   Chen, Yen Jen ^e   Mirasol, Roberto ^f   Tay, Boon Keng ^g   Shah, Ghazanfar Ali ^h   Khan, Mansoor Ali ⁱ   Tam, Frances ^j   Hall, Belinda J ^k   Thiebaud, Daniel ^k  

^a UNIVERSITY OF THE PHILIPPINES   (Philippines)

^b Department of Orthopaedic Surgery   (Malaysia)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f St Luke's Medical Centre   (Philippines)

^g SINGAPORE GENERAL HOSPITAL   (Singapore)

^h Doctor's Hospital   (Pakistan)

ⁱ Mideast Medical Centre   (Pakistan)

^j ELI LILLY AND COMPANY   (United States)

^k ELI LILLY AUSTRALIA PTY LTD   (Australia)

more..

Author keywords

Adherence; Bisphosphonate; Osteoporosis; Raloxifene

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGE; AGED; ARTICLE; ASIAN; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; EDUCATION; FEMALE; FRACTURE; FRAGILITY FRACTURE; HONG KONG; HOT FLUSH; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MALAYSIA; MENOPAUSE; NAUSEA; PAKISTAN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHILIPPINES; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RACE; RISK; SINGAPORE; TAIWAN;

AGED; ALENDRONATE; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; QUESTIONNAIRES; RALOXIFENE;

EID: 33847311328     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-006-0735-7     Document Type: Article

References (31)

1. JJ Stepan F Alenfield G Boivin JHM Feyen P Lakatos 2003 Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis Endocr Regul 37 227 240
2. VL Baker U Ulrich 1999 Estrogen replacement and alternatives for the prevention and treatment of osteoporosis Curr Probl Obstet Gynecol Fertil 22 80 119
3. NH Miller 1997 Compliance with treatment regimens in chronic asymptomatic diseases Am J Med 102 43 49
4. L Osterberg T Blaschke 2005 Adherence to medication N Engl J Med 353 487 497
5. DH Solomon J Avorn JN Katz JS Finkelstein M Arnold JM Polinski MA Brookhart 2005 Compliance with osteoporosis medications Arch Intern Med 165 2414 2419
6. J Fawcett 1995 Compliance: definitions and key issues J Clin Psychiatry 56 4 8
7. J Melnikow C Kiefe 1994 Patient compliance and medical research J Gen Intern Med 9 96 105
8. CL Peck NJ King 1985 Compliance and the doctor-patient relationship Drugs 30 78 84
9. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535 1541
10. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk fracture in women with low bone density but without vertebral fractures JAMA 280 2077 2082
11. UA Liberman SR Weiss J Bröll HW Minne H Quan NH Bell J Rodriguezportales RW Downs J Dequeker M Favus E Seeman RR Recker T Capizzi AC Santora A Lombardi RV Shah LJ Hirsch DB Karpf 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N Engl J Med 333 1437 1443
12. CH Chesnut III MR [tmp] McClung KE Ensrud NH Bell HK Genant ST Harris FR Singer JL Stock RA Yood PD Delmas U Kher S Pryortillotson AC Santora 1995 Alendronate treatment of the postmenopausal osteoporosis woman: effect of multiple dosages on bone mass and bone remodeling Am J Med 99 144 152
13. B Ettinger A Pressman J Schein 1998 Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions and discontinuation J Manag Care Pharm 4 488 492
14. SJ Boccuzzi SH Foltz MA Omar 2005 Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates Osteoporos Int 16 S3 OC10
15. PD Delmas NH Bjarnason BH Mitlak AC Ravoux AS Shah WJ Huster M Draper C Christiansen 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N Engl J Med 337 1641 1647
16. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant C Christiansen PD Delmas JR Zanchetta J Stakkestad CC Gluer K Krueger FJ Cohen S Eckert KE Ensrud LV Avioli P Lips SR Cummings 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene JAMA 282 637 645
17. BW Walsh LH Kuller RA Wild S Paul M Farmer JB Lawrence AS Shah PW Anderson BM Rifkind JE Rossouw 1998 Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women JAMA 279 1445 1451
18. GC Davies WJ Huster W Shen B Mitlak L Plouffe Jr A Shah FJ Cohen 1999 Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women Menopause 6 188 195
19. SR Cummings S Eckert KA Krueger D Grady TJ Powles JA Cauley L Norton T Nickelsen NH Bjarnason M Morrow ME Lippman D Black JE Glusman A Costa VC Jordan 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women JAMA 281 2189 2197
20. GC Davies WJ Huster Y Lu L Plouffe Jr M Lakshmanan 1999 Adverse events reported by postmenopausal women in controlled trials with raloxifene Obstet Gynecol 93 558 565
21. C Turbí G Herrero-Beaumont JC Acebes A Turrijos J Grana R Miguelez JA Sacristan F Marin 2004 Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study Clin Ther 26 245 256
22. JR Zanchetta C Hakim C Lombas 2004 Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis Curr Ther Res 65 470 480
23. ANA Tosteson MR Grove CS Hammond MM Moncur GT Ray GM Hebert AR Pressman B Ettinger 2003 Early discontinuation of treatment for osteoporosis Am J Med 115 209 216
24. RB Haynes DL Sackett ES Gibson DW Taylor BC Hackett RS Roberts AL Johnson 1976 Improvement of medication compliance in uncontrolled hypertension Lancet 1 1265 1268
25. P Lips NM van Schoor 2005 Quality of life in patients with osteoporosis Osteoporos Int 16 447 455
26. Recker R, Kendler D, Recknor C, Rooney T, Lewiecki EM, Utian WH, Cauley J, Lorraine J, Qu Y, Kulkarni PM, Plouffe L, Stock J (2005) Effects of raloxifene or alendronate on fracture risk reduction: results from the EVA (Evista®/Alendronate Comparison) Trial. Presented at the American Society for Bone and Mineral Research annual meeting, September 23-27, 2005, Nashville, TN (presentation number F425)
27. T Nakamura JL Liu H Morii QR Huang HM Zhu Y Qu E Hamaya D Thiebaud 2006 Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis J Bone Miner Metab 24 414 418
28. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460
29. D Weycker D Macarios G Oster 2005 Adherence with weekly versus daily bisphosphonate therapy among women with postmenopausal osteoporosis J Bone Miner Res 20 suppl 1 S280 281
30. JS [tmp] McCombs M Cody K Besinque G Borok D Ershoff S Groshen J Hay KA Johnson MB Nichol MT Nye 1995 Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser Permanente/USC Patient Consultation Study Clin Ther 17 1188 1206
31. J Melnikow C Kiefe 1994 Patient compliance and medical research: issues in methodology J Gen Intern Med 9 96 105